Question

In: Accounting

Biotech Limited Financial year end 30 June 2020 You are an auditor in Smit & Chandra,...

Biotech Limited

Financial year end 30 June 2020

You are an auditor in Smit & Chandra, a mid-tier audit firm. Your firm is the incumbent auditor on Biotech Ltd, a pharmaceutical company. Since the previous audit, the company has listed on the Australian Securities Exchange which means the company has to meet additional reporting regulations. Due to rapid growth, Biotech Ltd is financially stretched and its accounting systems are struggling to cope with the growth in the business. You recently read an article in the Australian Financial Review, which stated that Biotech Ltd is currently under investigation by the Australian Taxation Office (ATO) for alleged failure to pay the appropriate amount of Pay As You Go (PAYG) tax on their payroll.

Biotech Ltd is a pharmaceutical company, developing drugs to be licensed for use around the world. Products include medicines such as tablets, medical gels and creams. The market is very competitive, encouraging rapid product innovation. New products are continually in development and improvements are made to existing formulations. Drugs must meet very stringent regulatory requirements prior to being licensed for production and sale. You are aware that during the 2020 financial year, Biotech Ltd lost several customer contracts to overseas competitors.

Biotech Ltd approached its bank during the year to extend its borrowing facilities. An extension of $20 million was sought to its existing loan to support the on-going development of new drugs. The long-term borrowings are subject to debt covenants in which the company must maintain a current ratio of 3.5:1.

In addition, the company asked the bank to make cash of $5 million available if an existing court case against the company is successful. The court case is being brought by an individual who suffered severe side effects when participating in a clinical trial in 2016.

On 8 June 2020, the Company announced to the market it had been the victim of a cyber-security incident that resulted in supplier and customer details being disclosed on the dark web. The Company is assessing the costs of the incident and the subsequent reduction in revenue. The Company expects this to have a material impact on future earnings.

In December 2019, the internal audit department of Biotech Ltd performed a review of the operation of controls over processing of overtime payments in the Payroll department. It was found that the company’s specified internal control procedures in relation to the processing of overtime payments were not followed.

Below are some results of the analytical review procedures performed by the Senior Auditor (David) during the planning stage:

Sales                                                                                                            12.5% decrease since prior year

Net profit after tax                                                                                20% decrease since prior year

Accounts payable                                                                                   15% decrease since prior year

Cash at Bank                                                                                             16% increase since prior year

Accounts receivable                                                                              18% increase since prior year

Inventories                                                                                               6%   increase since prior year

Current ratio:                                                                                            3.6:1

Debt to Equity ratio:                                                                               0.6

Minutes from the Audit Planning meeting with Simon Jones (Finance Director of Biotech Ltd) held on 30th April 2020:

Due to the current government restrictions, the planning meeting with Simon Jones was held via Zoom. In attendance at the meeting was the Audit Partner (Michael), the Audit Manager (Amanda) and the Audit Senior (David).

The following key items were discussed during the meeting:

  • Mr Jones raised concerns about the conduct of the previous audit, stating numerous examples of when he and his staff had been interrupted when they were busy. He stated that he wanted guarantees that this year's audit will be more efficient, less intrusive and cheaper, otherwise he will seek an alternative auditor in future.
  • Michael reminded Mr Jones that fees relating to the audit engagement from the previous year were still outstanding.
  • Both Michael and Mr Jones also discussed the range of non-audit services provided to Biotech Ltd, which includes payroll preparation, tax computation and advice.
  • Mr Jones gave the audit team an update on the court case pertaining to the individual who suffered severe side effects from a company trial (refer above). According to legal advice provided to Mr Jones by the company’s legal counsel, it is more likely than not that Biotech will lose the court case, which would result in a significant amount of cash having to be paid as a settlement.
  • Amanda asked Mr Jones if he considered the decline in profitability as an indicator of a material uncertainty surrounding the going concern assumption. Mr Jones responded by saying, “Look, everything might seem dire, but we have it under control. We will be here this time next year, so keep that in mind”. Michael then looked at Amanda and David and said, “Make sure that you mention the conversation that we have just had with Mr Jones about the appropriateness of the going concern assumption in the audit working papers. This should be sufficient enough audit evidence for us.”
  • Mr Jones also mentioned the following: “As you know, Biotech Ltd has a Goodwill asset on the balance sheet. This is an indefinite useful life intangible asset. In accordance with the Accounting Standards (AASB 138), we are required to test the asset for impairment every year. We usually prepare a Value in Use calculation based on discounted future cash flows that we expect to generate in the next five years. I have completed this year’s calculation by rolling forward the prior year’s calculation and have just updated the dates. There was no need to update the future cash flow figures.”

The Audit Team

The audit team consists of 4 people. The partner is Michael. He has been the audit partner on the Biotech Ltd audit for 6 years. The audit manager is Amanda. This is Amanda’s first time on the Biotech Ltd audit. David is the audit senior and is responsible for the initial audit planning. David has recently completed the Graduate Diploma of Chartered Accounting. David has just been offered a well-paying accountant position at Biotech but he has not yet decided whether to accept the position. The graduate on the audit is Audrey. Audrey’s friend is the receptionist at Biotech Ltd. The receptionist has no accounting knowledge and has no involvement with the recording or processing of accounting transactions.

Accounts Receivable / Sales Accounting Cycle and Internal Control System

At the end of each month, the sales manager determines the amount of products required to meet sales demand for the following month based on sales orders received. He reviews the sales orders received from customers and then prepares the pre-numbered inventory requisition forms, which he then sends to the warehouse managers so that they can prepare the goods for delivery. One copy of the sales order and inventory requisition form is sent to the warehouse, one copy is sent to the accounts receivable department and one copy is filed in the sales department.

The warehouse prepares the goods for delivery to the customers and generates the delivery document. When the goods have been delivered, the signed delivery document, which includes the delivery details, is forwarded to the accounts receivable department. The other copy is filed in the warehouse. The accounts receivable clerk matches the signed delivery document with the sales order and inventory requisition form. Once satisfied that all of the details agree, the clerk generates the sales invoice. Once generated, the clerk does another check to ensure that all details per the sales invoice agrees to the delivery document and sales order. Once satisfied, she writes “checked” on the sales invoice and sends it to the customer. At the end of every week, a different clerk in the Accounts Receivable team reviews the bank statements for receipt of payments from customers and performs a reconciliation against the sales invoices. Once a customer has paid the sales invoice, the clerk stamps “received” on the sales invoice and files that along with all the other documents in date order.

The walk-through of the accounts receivable/sales cycle confirmed that the accounting and internal control system was working as documented above.

Test of control:

As part of the audit, Audrey tested the controls over the accounts receivable system. She selected a sample of twenty sales transactions and tested the control that all details had been checked. Out of the 20 sales transactions that were selected for testing, 5 sales invoices in the sample did not have the word “checked” written on them. When documenting the results of the test performed, Audrey concluded that the internal control did not operate effectively and consistently throughout the year but that no further audit work is required.

Substantive test

In order to test the occurrence of the sales transactions, Audrey selected a sample of sales invoices and traced them to the General Ledger to test that they were properly recorded.

Subsequent events not previously mentioned

  • One of Biotech Ltd’s major customers went into liquidation in July 2020. The balance due from the customer at 30 June 2020 was $564,000. This is a material amount. There has been no provision/allowance for doubtful debts raised for this debtor in the financial statements for the year ended 30 June 2020. Biotech Ltd’s legal adviser stated in a telephone call that that the probability of any funds being received from the debtor is remote.

  • On 2 July 2020, Biotech Ltd declared a one-for-five rights issue of 100,000 shares at $2.20. These shares were payable in full on 31 July 2020.

Identify and Explain the inherent risk and business risk and their types for the above case study?

Solutions

Expert Solution

  Business risk relates to the financial statements and affects overall audit risk; inherent risk applies to an individual audit area. Inherent risk is explicitly included in the professional standards and the audit‐risk model while business risk is not and has only an indirect bearing on the model.Business risk and inherent risk both bear on the audit; the audit risk model; and the nature, timing, and extent of work performed. Inherent risk and business risk bear an inverse relationship to detection risk and have a direct effect on the level of work performed. Neither risk can be eliminated totally and neither is controllable by the auditor. Management can take steps to affect the level of inherent risk, but the perceptions of users of the financial statements bear on business risk.

  Inherent risk is defined as the possibility of incorrect or misleading information in accounting statements resulting from something other than the failure of controls.

  Business risk is the exposure a company or organization has to factor(s) that will lower its profits or lead it to fail. Anything that threatens a company's ability to achieve its financial goals is considered a business risk.

In the above casestudy reveals the different types inherent risk with in the firm . The business is under supervision of the regulatory authority becasuse of improper recording of buisness transactions and ilegitimate business things. The managent of this concern is not efficient in their operations and they have making many mistakes in recording and keeping business transaction. They are not following the accounting standars for their financial transactions. The previous audit reports shows the misappropriation of figures and the accounts they maintained for accounts receivable, sales are not properly maintained. This shows the financial recordings are fraudlent in nature.

The audi team is not an expert in nature this is an limiting factor of the firm.The business is in a trouble that they face a suit against them because its a pharmaceutical copmany thy made many tests and its not authorised level and one of its tester suffered severe sideeffects. The reputation also declined.

Business risks   

  • opportunity-based – risk from choosing one option over other options (such as buying a new property)
  • uncertainty-based – risk from uncertain or unknown events (such as natural disasters or loss of suppliers)
  • hazard-based – risk from dangerous materials or actions (such as using hazardous chemicals or working at heights)

  

The Bio tech Ltd faces business risks also. they face competition from all over the orld because they produce pharmaceutics . The invention in the medicines create more human related issues they also face like a problem in their new product development stage. It will affect their reputation and goodwill and leads to the financial loss.

  


Related Solutions

Biotech Limited Financial year end 30 June 2020 You are an auditor in Smit & Chandra,...
Biotech Limited Financial year end 30 June 2020 You are an auditor in Smit & Chandra, a mid-tier audit firm. Your firm is the incumbent auditor on Biotech Ltd, a pharmaceutical company. Since the previous audit, the company has listed on the Australian Securities Exchange which means the company has to meet additional reporting regulations. Due to rapid growth, Biotech Ltd is financially stretched and its accounting systems are struggling to cope with the growth in the business. You recently...
Biotech Limited Financial year end 30 June 2020 You are an auditor in Smit & Chandra,...
Biotech Limited Financial year end 30 June 2020 You are an auditor in Smit & Chandra, a mid-tier audit firm. Your firm is the incumbent auditor on Biotech Ltd, a pharmaceutical company. Since the previous audit, the company has listed on the Australian Securities Exchange which means the company has to meet additional reporting regulations. Due to rapid growth, Biotech Ltd is financially stretched and its accounting systems are struggling to cope with the growth in the business. You recently...
You are an auditor in Smit & Chandra, a mid-tier audit firm. Your firm is the...
You are an auditor in Smit & Chandra, a mid-tier audit firm. Your firm is the incumbent auditor on Biotech Ltd, a pharmaceutical company. Since the previous audit, the company has listed on the Australian Securities Exchange which means the company has to meet additional reporting regulations. Due to rapid growth, Biotech Ltd is financially stretched and its accounting systems are struggling to cope with the growth in the business. You recently read an article in the Australian Financial Review,...
Max is an auditor on the low end limited engagement for the year ended 30 June...
Max is an auditor on the low end limited engagement for the year ended 30 June 2012. Jordan has performed a number of tests in relation to accounts payable. Selected a number of suppliers' invoices and checked that the pricing and discount terms have been reviewed and authorized by the purchase manager. Three out of 20 invoices tested had not been authorized and incorrect discounts were recorded for these invoices. A follow-up of the three samples with deviations did not...
Days Ltd's financial year ended on 30 June 2020. The following events occurred between the end...
Days Ltd's financial year ended on 30 June 2020. The following events occurred between the end of the reporting period and the date the directors of Edwards Ltd expect to authorise the financial statements for issue: On 3 July 2020, directors proposed a final dividend of $120,000. On 15 July 2020, Days Ltd took delivery of building materials (inventory). Building materials were purchased from a Chinese manufacturer. Building materials were in transit at the end of the reporting period. An...
Leopard Ltd's financial year ended on 30 June 2020. The following events occurred between the end...
Leopard Ltd's financial year ended on 30 June 2020. The following events occurred between the end of the reporting period and the date the directors of Leopard Ltd expect to authorise the financial statements for issue: On 25 July 2020, directors proposed a final dividend of $180 000 which requires approval at the annual general meeting. On 15 July 2020, the financial cost of inventory shipped from overseas is determined. The inventory was received in June 2020 and the cost...
The Statements of Financial Position for Lexington Limited as at 30 June 2019 and 30 June...
The Statements of Financial Position for Lexington Limited as at 30 June 2019 and 30 June 2020 are provided below: Lexington Ltd Statement of Financial Position as at 30 June 2020 2019 Assets $ $ Cash at bank 64,580 38,400 Accounts Receivable 82,800 35,000 Inventory 112,500 102,850 Prepaid Advertising 14,400 14,000 Machinery 310,000 282,500 Less: Accumulated Depreciation (50,000) (52,000) Total Assets $534,280 $420,750 Liabilities Accounts Payable 157,000 59,300 Dividends payable 15,000 - Wages payable 20,700 25,000 Loan 125,000 130,000 Total...
The Statements of Financial Position for Kiwi Limited as at 30 June 2019 and 30 June...
The Statements of Financial Position for Kiwi Limited as at 30 June 2019 and 30 June 2020 are provided below: Kiwi Limited Statement of Financial Position as at 30 June 2019 2020 Assets $ $ Cash at Bank 68,000 56,000 Accounts Receivable 121,000 139,000 Inventory 44,000 41,000 Land 241,000 241,000 Plant and Machinery 319,000 414,000 Less: Accumulated Depreciation (10,000) (89,000) Total Assets $783,000 $802,000 Liabilities Accounts Payable 55,000 54,000 Tax Payable 16,000 23,000 Loan 536,000 362,000 Total Liabilities $607,000 $439,000...
Tukai is a listed limited-liability company with a year-end of 30 June. Tukai’s main activity is...
Tukai is a listed limited-liability company with a year-end of 30 June. Tukai’s main activity is selling health products to the public. Products sold range from soap, perfume and herbal supplements. Products are purchased from approximately 100 different suppliers around Asian countries. Tukai has 20 stores in 5 different countries. Tukai is managed by Karl Kalulu who is an accountant with CPA from Australia and with his influence has a well-trained staffed internal audit department, who report on a regular...
You are the auditor of Super Fresh Pty Ltd (SPFL) for the year ended 30 June...
You are the auditor of Super Fresh Pty Ltd (SPFL) for the year ended 30 June 2019. SPFL is a manufacturer of tinned shellfish products. It purchases fresh shellfish from local suppliers, and frozen shellfish from South East Asia and processes it into tins at its Darwin factory and then transports it by road to supermarkets around Australia. You became aware of the following material event: On 1 July 2019 a customer at a Palmerston supermarket purchased a tin of...
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT